1174196-88-3Relevant academic research and scientific papers
NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE
-
Page/Page column 46; 48; 49, (2017/08/01)
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the s
Discovery of selective PDE4B inhibitors
Naganuma, Kenji,Omura, Akifumi,Maekawara, Naomi,Saitoh, Masahiro,Ohkawa, Naoto,Kubota, Takashi,Nagumo, Hiromitsu,Kodama, Toshiyuki,Takemura, Masayoshi,Ohtsuka, Yuji,Nakamura, Junji,Tsujita, Ryuichi,Kawasaki, Koh,Yokoi, Hirotsugu,Kawanishi, Masashi
scheme or table, p. 3174 - 3176 (2010/03/24)
In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.
